We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/9/2021 13:57 | Fwiw - small column piece in the IC today saying Buy - good value basically | value viper | |
24/9/2021 08:13 | Christopher Mills mentions Clinigen (CLIN) at 16:58 in the latest Interview with PIWORLD Watch the video here: Or listen to the podcast here: | tomps2 | |
21/9/2021 17:03 | Some more very large trades reported after close and I can't think they were sells! I hope Elliot or BofA are still adding | badg | |
20/9/2021 15:54 | Very strong afternoon, glad I didn't sell. Well I am for now anyway, we all know that can change. | hpcg | |
20/9/2021 15:42 | BoA seems to have increased a bitStill wondering whether Elliott will have also | value viper | |
20/9/2021 14:42 | That's no longer a may. | essentialinvestor | |
17/9/2021 09:11 | Some selling late in the day yesterday may have been mugged. | essentialinvestor | |
16/9/2021 21:50 | Well that is a second warning, although interspersed with some hope. The product division appears to be the problem….big bet placed on proleukin is not coming good.it May recover but the longer the disruption continues, the greater the chances that a better product takes market share. The share price will recover when the health sector normalises or the company limps along for a couple of years and is sufficiently strong to take a write down…it can then get out from that shadow. The number of wins for services such as cliniport show the potential for a better cleaner business….but what is it worth on a sum of the parts basis broken up? Beware a cheap MBO backed by PE of the good division leaving the rump as a zombie. | whatja | |
16/9/2021 17:14 | Well I don't understand.. almost a million buys in the 630's and yet a few smaller trades at day end and we finish under 600!What is going on? | badg | |
16/9/2021 16:24 | What a shower, Paying out a dividend with those results and yet trying to alleviate their debt at the same time. Would not surprise me to see a placing with this share price action. | marvelman | |
16/9/2021 16:11 | Another few, that's my lot. | essentialinvestor | |
16/9/2021 15:28 | Well I bought 3 more lots myself.. can't buy any more! | badg | |
16/9/2021 12:26 | Wouldn't surprise if Elliott uses this dip to increase their stake ..... let's see | value viper | |
16/9/2021 12:00 | Well someone has picked up quite a few in the last 15 mins at 641 100,000 blocks | badg | |
16/9/2021 11:11 | Indeed, although their charges are too rich for my blood. Had some, today opens up the possibility of corporate action, just imv obvs. | essentialinvestor | |
16/9/2021 11:04 | Clinigen is a large holding in the OIT - they are proving to be outstanding pickers of companies that have been on the receiving end of takeovers : Vectura and Elementis to mention a couple. | value viper | |
16/9/2021 09:12 | Not sure why the share price has reacted poorly today…..have skimmed the business report and there are certainly lots of future positives alongside some caution about Proleukin sales. Nothing particularly different from the last trading update, positive if anything. In the absence of M&A we will need to wait for the HY results trading update in Jan/Feb to see if the promised increase in business contracts is flowing into profits and cash. The rationale for not writing down Proleukin must be a key audit issue…they are probably not strong enough to take that blow now, but the bottom will be when they do it. | whatja | |
16/9/2021 08:39 | I clearly jumped back on board a little early, before I had wanted, to in light of the Elliot story and have topped up/averaged down this morning.Hoping that the opportunity at this level is a catalyst for some interest/activity. | badg | |
16/9/2021 08:31 | Window to add maybe on this dip with potential for things to liven up - Elliott for starters - is there possibly PE interest here also | value viper | |
14/9/2021 09:27 | I tentatively bought back in yesterday - off today and want some more but will watch and wait for a few hours. Have re read the trading update in July and we've had all the negative covid related issues stated so i am hoping there are no nasty surprises on Thursday. As previously said, had planned to stay out of these until next year once hospital treatments had normalised but Elliot at al has changed that! | badg | |
11/9/2021 20:20 | Thank you for that. Helpful counsel. | badg | |
11/9/2021 16:52 | Elliott don’t seem to own shares but have a stake through other means…they could easily divest if no bidder emerges…..they don’t necessarily bid themselves but want to trigger others. The earlier bid situation at UDG highlights the potential for the services division. I will be selling if they sell one division as it will be the better one that gets offers. Plenty of upside for speculators to buy into….a full bid unlikely to be accepted by the board at less that 800. Only last year they thought 1000 was too low. A speculative bubble is likely in The next month….just have to wait and see if anything happens or if it gently deflates. | whatja | |
11/9/2021 11:59 | I held a lot of these until just before last results and sold out around 820Was waiting for the next set of results to see how delta has still influenced hospital cancer treatments but have been blindsided by this Elliot 5% and the sudden rise yesterday! I was offline for the days. Any thoughts? | badg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions